26 August 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2022 PBAC intracycle meeting are now available.

Insights:

• Burosumab was recommended with a very high base case incremental cost effectiveness ratio, "the PBAC considered that the resultant incremental cost effectiveness ratios were reasonable ($255,000 - $355,000/QALY gained for the paediatric population and $255,000 - $355,000/QALY gained for the adult population)."
• The PBAC recommended the PBS listing of daratumumab with hyaluronidase (Darzalex SC) without the need for a price reduction. Nonetheless, a risk sharing agreement will be required.
• The PBAC recommended the PBS listing of faricimab for patients with age-related macular degeneration and patients with diabetic macular oedema. While the Public Summary Document for the former is clear that a risk sharing agreement will be required, it is not clear whether one will be required for the latter.
• The PBAC recommended the PBS listing of trientine dihydrochloride and trientine tetrahydrochloride. Both applicants/sponsors offered a price reduction; it was adequate for the former but not for the latter.

Read PBS News